Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology
about
Role of HIV in amyloid metabolismMeta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic CriteriaClinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkersAlzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful agingOrigins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement.Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's DiseaseUpdate on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease.Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.Comparison of two analytical platforms for CSF biomarkers of Alzheimer's diseaseAnxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment.Intracellular clusterin interacts with brain isoforms of the bridging integrator 1 and with the microtubule-associated protein Tau in Alzheimer's diseaseQualification of a surrogate matrix-based absolute quantification method for amyloid-β₄₂ in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometryImproving CSF Biomarkers' Performance for Predicting Progression from Mild Cognitive Impairment to Alzheimer's Disease by Considering Different Confounding Factors: A Meta-Analysis.Exploring the binding of BACE-1 inhibitors using comparative binding energy analysis (COMBINE).Executive function changes before memory in preclinical Alzheimer's pathology: a prospective, cross-sectional, case control study.Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's diseaseSphingolipid metabolism correlates with cerebrospinal fluid Beta amyloid levels in Alzheimer's diseaseFactors affecting Aβ plasma levels and their utility as biomarkers in ADNIDifferential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies.Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's diseaseFluid biomarkers in Alzheimer disease.Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.Alzheimer's disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodologyPlasma microRNA biomarkers for detection of mild cognitive impairment.Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease.Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platformsCerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease.Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease.Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia.A Luminex assay detects amyloid β oligomers in Alzheimer's disease cerebrospinal fluid.Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients.Circulating cell-free microRNA as biomarkers for screening, diagnosis and monitoring of neurodegenerative diseases and other neurologic pathologiesCSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's diseaseThe Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.Progress update: fluid and imaging biomarkers in Alzheimer's disease.A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging.Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.Consensus classification of posterior cortical atrophy.Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis.
P2860
Q26824179-89B22147-5CEE-4589-99E5-263165EFE450Q26864063-BCCEAAC2-9778-47E8-8E69-3DEA823D3C7AQ27008249-7D63AC1C-1D67-483E-9134-371D0D2E81F5Q28477836-99BB9A47-11EC-4333-94EC-F994C7D79FBBQ30572288-9806D964-F9F3-4E24-8F6F-0270A41FBC74Q30659251-46735237-9A99-4560-A74E-E095565DE70CQ30845482-E682A849-BEB0-4BE3-BB80-907C1978467FQ33687554-A25D683B-E823-4AE8-93C0-9459F2879E3EQ33757426-6A24BE7B-7E30-49FC-A4E0-117705D17404Q33924292-67D68A49-6075-4D83-B8CE-0C03187B2610Q33933612-628823A6-D6CC-4F8F-AC09-376FC1A1E11CQ34157882-FB585CEE-C2A9-4534-AAAF-E41BC964E7BBQ34349522-4C3B5AF8-B70C-4A70-AF30-67704C937E05Q34394583-DC47AA53-9523-4357-B90D-12F13B60BC5DQ35048396-F8093E95-1383-4D03-8FB3-FC183742A3A8Q35284971-9405B1FB-6411-441A-B65B-9FD0A5280DBBQ35566575-6CD55441-047C-44D4-A93F-35BDC4D7F846Q35821382-9B8B5CA0-D6C3-44BF-BB43-851CD2D2FBE0Q35938561-F34FD67B-6358-4B69-BF6E-8E7F0E9767EBQ35997824-E1AAA029-EA60-4F97-9E7A-2A61BE47D222Q36186513-586A6F17-04AF-4F72-85E1-08E99709A70EQ36276506-1480B17A-B1E8-4537-BDA5-DF5AF1429F32Q36298550-B15852EF-CFBE-41A5-A1A2-D9C8056FC41BQ36380583-E812FB78-DFA7-44EF-AA36-6F7CC03DD08BQ36439886-D787DCD3-BABD-4660-9C3C-54637733DBCBQ36482533-0741716B-60DD-412D-8657-2A8CFDE5B722Q36626657-68A4C465-F0BB-4AA4-B36B-431C9DB95CC1Q36865597-DCD3E5A9-3D77-4891-BD96-3CB5E22D7E8DQ36933691-65CE6AB7-68DC-4CB8-A3E0-6F7906B0EEB9Q36976390-C7CFE076-BE6A-444C-B038-DE9E8AE48EAFQ37053871-794586C4-7DC6-4EA6-8ECD-B764E08A0B05Q37071555-6609C978-5144-4042-B950-C2E32DBDD8F4Q37158033-1684FE1C-6DE0-41B9-9916-02E37DD3837FQ37266166-19911E60-777B-442A-9F6C-6DC24CBB386FQ37451440-FC40276C-A197-4B87-B171-B6D4D575A89EQ37626382-D0C4A319-305C-403E-BE42-2AEF4A6769EEQ37710439-B0DF22A6-2BA0-4940-B685-A4B30A4C610DQ38289739-999DE78C-D9E6-446C-B61B-BFC6D3BC10E7Q38750711-4D4C035C-F5DC-4290-AAC9-5B3674E0CA1EQ38960660-0A92FBFF-CC96-449F-A440-750A5D6EBCB2
P2860
Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Comparison of analytical platf ...... sease amyloid plaque pathology
@ast
Comparison of analytical platf ...... sease amyloid plaque pathology
@en
type
label
Comparison of analytical platf ...... sease amyloid plaque pathology
@ast
Comparison of analytical platf ...... sease amyloid plaque pathology
@en
prefLabel
Comparison of analytical platf ...... sease amyloid plaque pathology
@ast
Comparison of analytical platf ...... sease amyloid plaque pathology
@en
P2093
P2860
P50
P1433
P1476
Comparison of analytical platf ...... sease amyloid plaque pathology
@en
P2093
Chengjie Xiong
Hugo Vanderstichele
Leslie M Shaw
P2860
P304
P356
10.1001/ARCHNEUROL.2011.105
P577
2011-05-09T00:00:00Z